AI assistant
ImmunityBio, Inc. — Director's Dealing 2021
May 26, 2021
31529_dirs_2021-05-25_d2a53c80-8a91-43a0-8bd1-ca2da80940c0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-05-21
Reporting Person: Simon Barry J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-21 | Common Stock | S | 14990 | $16.0883 | Disposed | 3212517 | Direct |
| 2021-05-24 | Common Stock | S | 21223 | $16.0237 | Disposed | 3191294 | Direct |
| 2021-05-25 | Common Stock | S | 88787 | $16.1828 | Disposed | 3102507 | Direct |
Footnotes
F1: Represents the weighted average share price of an aggregate total of 14,990 shares sold in the price range of $16.00 to $16.26 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: Represents the weighted average share price of an aggregate total of 21,223 shares sold in the price range of $16.00 to $16.115 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 88,787 shares sold in the price range of $16.00 to $16.425 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.